// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Donor SIRPa Polymorphism Modulates the Innate Immune Response to Allogeneic Grafts.

H. Dai - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

IL-12

Donor Warm Ischemic Time >80min Is an Important Predictor of Kidney Graft Survival from Donors After Cardiac Death.

J. Chen - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

vasopressin Injection

Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care.

Kishan Shani - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer.

Jin Yong Patrick Park - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Gemcitabine

Dual Role for Caspase-3 in the Regulation of Tubular and Microvascular Damage Post-Renal Ischemia-Reperfusion Injury.

B. Yang - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Primary tumor location and survival in general population with metastatic colorectal cancer (mCRC).

Shahid Ahmed - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Impact of time to surgery in locally advanced rectal cancer patients.

Madiha Naseem - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Echinocandins in Lung Transplant Recipients (LTRs).

Y. AlJishi - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of Academic Detailing with Prescribers as an Antimicrobial Stewardship Intervention in Solid Organ Transplant Patients.

M. So - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Oncopre: A new chemotherapy benefit prediction algorithm to assist treatment decision making.

Dimas Yusuf - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Effects of Anti-HLA Antibodies on Endothelial Expression and Serum Levels of Thrombomodulin in Kidney Recipients.

S. Beland - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Thrombomodulin alfa

Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer.

Pablo Emilio Serrano Aybar - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Efficacy of Trimethoprim-Sulfamethoxazole Prophylaxis for Nocardia in Solid Organ Transplant Recipients (SOTRs): Systematic Review and Meta-Analysis.

A. Alsharidi - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Trimethoprim/sulfamethoxazole

Employment Patterns After Kidney Transplantation: Rates, Contributing Factors, and Outcomes.

J. Kim - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer.

Irene S. Yu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Capecitabine

Ethnicity and Transplant Knowledge Among Canadian ESKD Patients.

D. Wong - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment.

Heinz-Josef Lenz - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Oxaliplatin

Ethnocultural Barriers to Pre-Emptive Kidney Transplantation: A Single Centre Retrospective Cohort Study.

A. Bansal - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ECOG performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients.

Akie Watanabe - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Capecitabine

Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.

Akina Natori - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved